Published in J Clin Invest on September 20, 2010
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med (2012) 1.32
Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res (2013) 1.16
Annular PIP3 accumulation controls actin architecture and modulates cytotoxicity at the immunological synapse. J Exp Med (2013) 1.09
Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood (2013) 0.94
Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev (2014) 0.94
Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment. Clin Cancer Res (2014) 0.90
CD28z CARs and armored CARs. Cancer J (2014) 0.89
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol (2013) 0.87
Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model. PLoS One (2012) 0.87
E3 ubiquitin ligase Cbl-b in innate and adaptive immunity. Cell Cycle (2014) 0.86
Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression. Front Immunol (2016) 0.83
The role of E3 ubiquitin ligase Cbl proteins in interleukin-2-induced Jurkat T-cell activation. Biomed Res Int (2013) 0.81
T-cell tolerance in cancer. Immunotherapy (2013) 0.79
Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules. Gene Ther (2015) 0.79
The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence. Ther Adv Vaccines (2013) 0.78
Enhancing adoptive T cell immunotherapy with microRNA therapeutics. Semin Immunol (2015) 0.77
A novel CBL-Bflox/flox mouse model allows tissue-selective fully conditional CBL/CBL-B double-knockout: CD4-Cre mediated CBL/CBL-B deletion occurs in both T-cells and hematopoietic stem cells. Oncotarget (2016) 0.76
New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies. Clin Cancer Res (2015) 0.76
Cbl-b: Roles in T Cell Tolerance, Proallergic T Cell Development, and Cancer Immunity. Inflamm Cell Signal (2015) 0.75
Serine Phosphorylation of SLP76 Is Dispensable for T Cell Development but Modulates Helper T Cell Function. PLoS One (2017) 0.75
Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy. Clin Cancer Res (2016) 0.75
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. Front Immunol (2017) 0.75
Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation. Front Immunol (2017) 0.75
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol (1994) 10.03
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17
The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods (1990) 6.52
Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J Exp Med (1996) 6.08
The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J Immunol (2000) 6.00
Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature (2006) 5.90
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol (2006) 4.98
Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol (2004) 4.21
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature (2000) 4.08
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2005) 4.06
Cancer immunotherapy: a treatment for the masses. Science (2004) 4.04
Cellular transcription factors and regulation of IL-2 receptor gene expression by HTLV-I tax gene product. Science (1988) 4.01
Cbl-b regulates the CD28 dependence of T-cell activation. Nature (2000) 3.89
CD28- T lymphocytes. Antigenic and functional properties. J Immunol (1993) 3.67
Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med (1982) 3.34
Immune responses in interleukin-2-deficient mice. Science (1993) 3.29
CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol (2003) 3.12
Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity (2004) 2.76
Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med (1998) 2.72
The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res (2007) 2.54
Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell (2003) 2.28
Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med (2006) 2.16
Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol (2001) 2.02
Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor. Immunity (2008) 1.85
A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J Exp Med (1998) 1.84
Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J Immunol (2006) 1.81
Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med (2009) 1.78
Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J Exp Med (1986) 1.62
Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo. J Immunol (2006) 1.62
Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med (2003) 1.55
CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J Exp Med (2002) 1.53
Resistance to CD4+CD25+ regulatory T cells and TGF-beta in Cbl-b-/- mice. J Immunol (2004) 1.50
Bcl-2 and Bcl-2-related proteins in apoptosis regulation. Curr Top Microbiol Immunol (1995) 1.48
Cbl-b is a negative regulator of receptor clustering and raft aggregation in T cells. Immunity (2000) 1.44
Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol (2009) 1.36
CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol (2000) 1.34
Adaptive tolerance and clonal anergy are distinct biochemical states. J Immunol (2006) 1.32
T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b. Mol Cell Biol (2008) 1.30
CD4+8- help prevents rapid deletion of CD8+ cells after a transient response to antigen. Eur J Immunol (1993) 1.29
Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. J Clin Invest (2007) 1.29
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med (2007) 1.28
The role of E3 ligases in autoimmunity and the regulation of autoreactive T cells. Curr Opin Immunol (2007) 1.22
CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J Immunol (1999) 1.19
Transcriptional regulation of the gene encoding the human C-type lectin leukocyte receptor AIM/CD69 and functional characterization of its tumor necrosis factor-alpha-responsive elements. J Biol Chem (1995) 1.19
Molecular regulation of T-cell anergy. EMBO Rep (2008) 1.16
Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen. J Immunol (2001) 1.15
Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells. J Immunol (1984) 1.15
The IL-2 receptor promotes proliferation, bcl-2 and bcl-x induction, but not cell viability through the adapter molecule Shc. J Immunol (1998) 1.11
Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia. Cancer Res (1980) 1.08
Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells. J Pathol (2009) 0.99
Adoptive T cell therapy of cancer. Curr Opin Immunol (2009) 0.97
Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR. Mol Ther (2009) 0.96
Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b. J Immunol (2005) 0.96
Selective delivery of augmented IL-2 receptor signals to responding CD8+ T cells increases the size of the acute antiviral response and of the resulting memory T cell pool. J Immunol (2002) 0.91
Proliferation and differentiation of CD8+ T cells in the absence of IL-2/15 receptor beta-chain expression or STAT5 activation. J Immunol (2004) 0.85
Casitas B-lineage lymphoma b inhibits antigen recognition and slows cell cycle progression at late times during CD4+ T cell clonal expansion. J Immunol (2008) 0.84
Mammary tumors with diverse immunological phenotypes show differing sensitivity to adoptively transferred CD8+ T cells lacking the Cbl-b gene. Cancer Immunol Immunother (2009) 0.84
The E3 ubiquitin ligase Cbl-b regulates expansion but not functional activity of self-reactive CD4 T cells. J Immunol (2009) 0.79
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol (2003) 11.48
Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity (2007) 10.83
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood (2008) 7.01
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A (2006) 5.50
Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A (2004) 4.56
Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol (2004) 4.21
Cancer immunotherapy: a treatment for the masses. Science (2004) 4.04
MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res (2010) 3.57
Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity (2004) 3.10
Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J Exp Med (2007) 3.05
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol (2005) 2.75
microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med (2010) 2.68
c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat Immunol (2002) 2.64
Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell (2003) 2.28
Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science (2012) 2.26
Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem (2003) 2.23
Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med (2006) 2.16
PKA-mediated phosphorylation regulates the function of activation-induced deaminase (AID) in B cells. Proc Natl Acad Sci U S A (2005) 2.13
Role of FIP200 in cardiac and liver development and its regulation of TNFalpha and TSC-mTOR signaling pathways. J Cell Biol (2006) 2.12
Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood (2006) 2.11
Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol (2005) 2.06
Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature (2004) 1.99
CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med (2004) 1.92
The E3 ubiquitin ligase c-Cbl restricts development and functions of hematopoietic stem cells. Genes Dev (2008) 1.92
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat Biotechnol (2012) 1.90
Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor. Immunity (2008) 1.85
Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med (2013) 1.78
Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation. Virology (2003) 1.69
In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire. J Immunol Methods (2006) 1.64
Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood (2013) 1.63
Inactivation of focal adhesion kinase in cardiomyocytes promotes eccentric cardiac hypertrophy and fibrosis in mice. J Clin Invest (2005) 1.61
Shaping of human germline IgH repertoires revealed by deep sequencing. J Immunol (2012) 1.55
Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med (2003) 1.55
CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J Exp Med (2002) 1.53
Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1alpha -deficient chimeric mice. Proc Natl Acad Sci U S A (2002) 1.52
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol (2008) 1.48
A comparative study of the cytotoxicity of silver-based dressings in monolayer cell, tissue explant, and animal models. Wound Repair Regen (2007) 1.44
Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest (2002) 1.39
Src-like adaptor protein regulates TCR expression on thymocytes by linking the ubiquitin ligase c-Cbl to the TCR complex. Nat Immunol (2005) 1.35
Deficiency of Cbl-b gene enhances infiltration and activation of macrophages in adipose tissue and causes peripheral insulin resistance in mice. Diabetes (2007) 1.33
Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. J Clin Invest (2007) 1.29
Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J Immunol (2008) 1.28
Cbl-b negatively regulates B cell antigen receptor signaling in mature B cells through ubiquitination of the tyrosine kinase Syk. J Exp Med (2003) 1.25
Local role for tumor necrosis factor alpha in the pulmonary inflammatory response to Mycobacterium tuberculosis infection. Infect Immun (2002) 1.22
Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med (2009) 1.21
Grb2 functions at the top of the T-cell antigen receptor-induced tyrosine kinase cascade to control thymic selection. Proc Natl Acad Sci U S A (2010) 1.20
Abnormal B-cell responses to chemokines, disturbed plasma cell localization, and distorted immune tissue architecture in Rgs1-/- mice. Mol Cell Biol (2004) 1.20
Enhanced transgene expression in quiescent and activated human CD8+ T cells. Hum Gene Ther (2004) 1.19
T cell receptor gene therapy for cancer. Hum Gene Ther (2009) 1.17
Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog (2013) 1.16
Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity. Blood (2011) 1.15
Specific patterns of Cdc42 activity are related to distinct elements of T cell polarization. J Immunol (2006) 1.14
Ubiquitin-dependent degradation of interferon regulatory factor-8 mediated by Cbl down-regulates interleukin-12 expression. J Biol Chem (2005) 1.11
PD-1 blockade: rescue from a near-death experience. Nat Immunol (2006) 1.11
Cbl and Cbl-b in T-cell regulation. Trends Immunol (2002) 1.11
Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J Virol (2010) 1.11
Deletion of the gene encoding c-Cbl alters the ability of osteoclasts to migrate, delaying resorption and ossification of cartilage during the development of long bones. Dev Biol (2003) 1.10
Induction of tolerance in CD8+ T cells to a transgenic autoantigen expressed in the liver does not require cross-presentation. J Immunol (2007) 1.09
Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge. J Virol (2011) 1.08
Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. Immunity (2007) 1.06
Negative regulation of lymphocyte development and function by the Cbl family of proteins. Immunol Rev (2008) 1.05
Constitutive endocytosis and degradation of the pre-T cell receptor. J Exp Med (2002) 1.05
Rab8 interacts with distinct motifs in alpha2B- and beta2-adrenergic receptors and differentially modulates their transport. J Biol Chem (2010) 1.04
Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28. Blood (2011) 1.04
Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother (2015) 1.04
Negative regulation of TCR signaling and T-cell activation by selective protein degradation. Curr Opin Immunol (2003) 1.03
Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells. Pancreas (2007) 1.02
Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells. Proc Natl Acad Sci U S A (2010) 1.01
Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities. Cytometry A (2008) 0.99
SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells. J Immunol (2010) 0.99
Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc Natl Acad Sci U S A (2002) 0.99
Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood (2012) 0.99
Molecular mechanisms underlying differential contribution of CD28 versus non-CD28 costimulatory molecules to IL-2 promoter activation. J Immunol (2002) 0.99
Apoptosis-linked gene 2-deficient mice exhibit normal T-cell development and function. Mol Cell Biol (2002) 0.99
Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Res (2012) 0.98
Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice. Oncogene (2003) 0.98
Grb2, a simple adapter with complex roles in lymphocyte development, function, and signaling. Immunol Rev (2009) 0.97
Direct regulatory role of NKT cells in allogeneic graft survival is dependent on the quantitative strength of antigenicity. J Immunol (2005) 0.97
HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. Blood (2011) 0.97
Src-like adaptor protein (SLAP) regulates B cell receptor levels in a c-Cbl-dependent manner. Proc Natl Acad Sci U S A (2006) 0.97
Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR. Mol Ther (2009) 0.96
Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. AIDS Res Hum Retroviruses (2004) 0.96
Mechanisms of antiprostate cancer by gum mastic: NF-kappaB signal as target. Acta Pharmacol Sin (2007) 0.96
A molecular dissection of lymphocyte unresponsiveness induced by sustained calcium signalling. Novartis Found Symp (2005) 0.96